Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oplunofusp - Ansun Biopharma

Next Previous
Drug Profile

Oplunofusp - Ansun Biopharma

Alternative Names: DAS 181-F02; DAS-181; DAS181-F04; Fludase; NEX DAS181; ParaDase

Latest Information Update: 10 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NexBio
  • Developer Ansun Biopharma; NexBio
  • Class Antivirals; Recombinant fusion proteins
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parainfluenza virus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III COVID 2019 infections; Parainfluenza virus infections
  • Phase II Influenza virus infections
  • No development reported Enterovirus infections; Metapneumovirus infections
  • Discontinued Polyomavirus infections; Respiratory syncytial virus infections

Most Recent Events

  • 01 Jun 2026 Independent Data Monitoring Committee (DMC) issues a positive recommendation following a prespecified interim efficacy and safety review of the phase III DAS181-3-01 trial
  • 28 Mar 2024 No recent reports of development identified for phase-I development in Enterovirus infections in USA
  • 28 Mar 2024 No recent reports of development identified for phase-I development in Metapneumovirus-infections in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top